Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy in High/Intermediate-Risk Stage I–IIA Non-squamous NSCLC Identified by 14-Gene Assay
2024-511185-37-00Phase 4Authorised
- Sponsor
- Razor Genomics Inc., Intergroupe Francophone De Cancerologie Thoracique
- Start
- Mar 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised trial of carboplatin, paclitaxel, docetaxel, vinorelbine, cisplatin and 1 more in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Razor Genomics Inc., Intergroupe Francophone De Cancerologie Thoracique. Primary endpoint: Disease-free survival (DFS) in mITT high/intermediate-risk population. Planned start Mar 2024; status: authorised.
02
Drugs
carboplatinpaclitaxeldocetaxelvinorelbinecisplatin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2024-511185-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511185-37-00.